Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
OBJECTIVES:
Primary
-
Determine the best response in patients with advanced or unresectable renal cell cancer treated with lenalidomide (CC-5013).
-
Determine the time to disease progression in patients treated with this drug.
Secondary
- Determine the safety of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 30 days and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Study Design
Outcome Measures
Primary Outcome Measures
- Efficacy (complete and partial response) []
Secondary Outcome Measures
- Toxicity []
- Adverse events []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed renal cell carcinoma (RCC)
-
Advanced or unresectable disease
-
At least 1 measurable lesion
-
No active brain metastases
-
Prior brain metastases allowed provided patient has been treated with radiotherapy or surgery AND remains asymptomatic for ≥ 6 months
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 70-100%
Life expectancy
- Not specified
Hematopoietic
-
Absolute neutrophil count ≥ 1,500/mm^3
-
Platelet count ≥ 100,000/mm^3
Hepatic
-
Bilirubin ≤ 1.5 mg/dL
-
AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
-
No hepatitis A, B, or C infection
Renal
- Creatinine ≤ 2.0 mg/dL
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective contraception
-
HIV negative
-
No known hypersensitivity to thalidomide
-
No other serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent
-
No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, localized prostate cancer, or superficial bladder cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
-
No more than 1 prior systemic immunotherapy regimen for RCC
-
No prior lenalidomide (CC-5013)
-
No prior or concurrent thalidomide
Chemotherapy
- No more than 1 prior systemic chemotherapy regimen for RCC
Endocrine therapy
- No more than 1 prior systemic hormonal therapy regimen for RCC
Radiotherapy
-
See Disease Characteristics
-
No concurrent radiotherapy
Surgery
-
See Disease Characteristics
-
At least 4 weeks since prior surgery and recovered
Other
-
No more than 1 other prior systemic therapy regimen for RCC
-
No other concurrent anticancer therapies
-
No other concurrent investigational agents
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10021 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Gnanamba V. Kondagunta, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 04-014
- MSKCC-04014